Patients with metastatic colorectal cancer who engaged in moderate exercise while undergoing chemotherapy tended to have delayed progression of their disease and fewer severe side effects from treatment, according to the results of a study, ‘Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405’, Journal of Clinical Oncology.
The researchers reported that even low-intensity exercise, such as walking four or more hours a week, was associated with a nearly 20 percent reduction in cancer progression or death over the course of the six-year study, said researchers from Dana-Farber Cancer Institute and Brigham and Women's Hospital,. The analysis hinted at a possible lengthening of survival in patients who reported greater physical activity, but the data were not statistically significant.
"What we found was that people who engaged in some type of physical activity had a statistically significant improvement in progression-free survival (PFS)," said Dr Jeffrey A Meyerhardt, of Dana-Farber, senior author of the study. "While there may also be an impact on overall survival, it was not statistically significant and should be studied further."
"Physically active patients in our study also appeared to tolerate chemotherapy better," said Dr Brendan Guercio, first author of the study which was conducted while he was working as a hospitalist at Brigham and Women's. "Total physical activity equivalent to 30 or more minutes of moderate daily activity was associated with a 27 percent reduction in severe treatment-related toxicities."
Previous studies have found that regular exercise can reduce the risk of disease recurrence and death from colon cancer that has not metastasized to other parts of the body. Researchers explained that this is the first study to examine associations of physical activity with survival in advanced, metastatic colorectal cancer.
Patients participated in a phase 3 study of chemotherapy for advanced colorectal cancer conducted by the Alliance for Clinical Trials in Oncology and sponsored by the National Cancer Institute. Within a month after beginning treatment, patients were invited to complete a questionnaire about their average physical activity over the previous two months. The final number of participants included 1,218 patients. While the data are significant, further research with a randomised prospective trial will help validate the results, the researchers said.
Based on the patients' descriptions, researchers quantified their physical activity in terms of metabolic equivalent task (MET)-hours per week - a standard measure used in research studies of exercise. Vigorous activity was defined as any activity requiring six or more METs, such as running, biking, tennis, skiing, or lap swimming. Non-vigorous activities included walking, climbing stairs or yoga.
Analysis of the data revealed a statistically significant difference in PFS - the length of time after the patient completed the questionnaire before the cancer progressed or the person died. The difference in PFS was almost 20 percent in favour of those who exercised more.
Meyerhardt added that the findings "help justify encouraging patients to exercise and referring patients to physical therapists or programmes like the YMCA LIVESTRONG programme that does small group training for patients with cancer."